Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-8.67%
$0.30
1% positive prob.
5-Day Prediction
-7.15%
$0.30
1% positive prob.
20-Day Prediction
-15.13%
$0.27
1% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -8.67% | -7.15% | -15.13% | 98.2% | Pending |
| Q2 2026 | BUY | +1.75% | +6.06% | +8.35% | 100.0% | Pending |
| Q1 2026 | BUY | +2.17% | +6.27% | +9.47% | 100.0% | +3.81% |
| Q3 2025 | BUY | +2.77% | +6.80% | +10.60% | 100.0% | +0.91% |
SEC 8-K filings with transcript text
Nov 13, 2026 · 98% conf.
1D
-8.67%
$0.30
5D
-7.15%
$0.30
20D
-15.13%
$0.27
2 ex99-1.htm
Exhibit 99.1
Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation
Dyadic to host earnings call on November 12, 2026, at 5:00 p.m. ET
FL — November 12, 2026 — Dyadic International, Inc. (NASDAQ: DYAI), doing business as Dyadic Applied BioSolutions (the “Company” or “Dyadic”), a biotechnology company developing and commercializing precision-engineered, animal-free recombinant proteins and enzymes, today reported financial results for the third quarter ended September 30, 2026. Highlights included the Company’s first direct commercial protein sales, broader third-party distribution, additional partner-commercialized products, new strategic development opportunities and progress across its C1 and Dapibus™ production platforms.
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors,” said Joe Hazelton, President and Chief Operating Officer. “While early sales remain modest and evaluation timelines are longer than anticipated, we are seeing increased sampling requests—particularly for transferrin—as we convert initial qualifications into potential business.
“Concurrently, partner-led commercialization is building momentum. Proliant is expanding promotion for C1-produced AlbuFree™ DX with additional products planned, Inzymes commercialized a second Dapibus-produced chymosin, and our alpha-lactalbumin collaborations are moving toward commercial-scale supply. Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs. We continue to evaluate all options to optimize the value of our platforms and assets, including financing alternatives and other opportunities aimed at strengthening our balance sheet, accelerating commercialization and maximizing shareholder value,” Mr. Hazelton added.
Recent Company Developments
Commercial Products & Market Adoption
First Direct Commercial Product Sales: During the third quarter, Dyadic recorded its first direct commercial product sales, primarily of recombinant transferrin and DNase I. Although initial sales were not material in amount, they are a milestone as they establish a direct-product revenue channel, alongside existing and potential partner-generated license, milestone and profit-sharing or royalty economics.
Expanded OEM Distribution: Integrated Biotherapeutics (IBT Bioservices) launched an initial portfolio of six Dyadic-produced research-use-only recombinant protein products through its distribution network. The companies are evaluating additional offerings, extending Dyadic’s potential reach across research, diagnostics, reagent and cell culture applications.
Growing Customer Engagement: Sampling requests and customer evaluations increased for human and bovine transferrin and other recombinant proteins. Dyadic is supporting customer testing and qualification with the objective of converting these engagements into repeat purchases and sustained product demand.
Proliant AlbuFree™ Product Commercialization and Expansion: Proliant Health & Biologicals continued commercial promotion of AlbuFree™ DX, an animal-free recombinant human serum albumin produced using Dyadic’s C1 platform, including performance data relevant to diagnostic assay blocking and protein stabilization. Proliant also presented analytical research reporting high purity, low endotoxin levels and molecular characteristics resembling native human serum albumin. In addition, Proliant outlined planned additions to the AlbuFree™ family: AlbuFree™ TX for cell culture media and AlbuFree™ CGT for cell and gene therapy applications. These planned extensions offer opportunities to broaden C1-enabled product adoption and potential recurring commercial revenue.
Second Commercial Chymosin Demonstrates Dapibus™ Versatility: In November 2026, Inzymes reported that the first commercial sale of the Company’s second chymosin product, camel chymosin produced with the Company’s Dapibus™ production strain, occurred in October 2026, achieving the first-commercial-sale milestone under the Inzymes agreement. The Company expects to receive the $225,000 milestone payment and recognize it as revenue in the fourth quarter of 2026.
Strategic Partnerships, Licensing & Product Development
Advancing Alpha-Lactalbumin Toward Commercialization: Advanced collaboration activities with BRIG BIO and Strive Nutrition to develop, scale and potentially commercialize Dapibus-produced bovine alpha-lactalbumin for next-generation nutrition products. The participants bring complementary protein de
Aug 12, 2026 · 100% conf.
1D
+1.75%
$0.90
Act: -12.49%
5D
+6.06%
$0.93
20D
+8.35%
$0.95
2 ex99-1.htm
Exhibit 99.1
Dyadic to host earnings call on August 12 at 5:00 pm ET
FL — August 12, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,
or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.
“Our strong second-quarter performance underscores Dyadic’s ongoing transformation into a commercial-stage biotechnology leader, “said Joe Hazelton, President and COO. “We are driving commercial launches and sales of recombinant proteins, securing recurring revenue through strategic partners, distribution and optimizing manufacturing yields across life sciences, food and nutrition, and bioindustrial markets. Simultaneously, leading global health, government, academic and industry collaborations continue to validate the speed, productivity, scalability and potential commercial viability of our proprietary C1 expression system, while advancing C1-produced antibodies, vaccine antigens and other biologics toward broader preclinical evaluation and potential future clinical and commercial adoption.”
Recent Company Developments
● Commercial Sales & Product Shipments: Advanced the recombinant protein portfolio through Q2 product shipments directly and through distribution partners. Subsequent to quarter-end, Dyadic completed shipments of six distinct recombinant protein products and generated initial pilot sales of recombinant transferrin and growth factors for cultivated-meat applications.
● OEM Distribution Progress: Initiated Q2 shipments to IBT Bioservices under Dyadic’s OEM distribution agreement, with additional shipments completed after quarter-end, supporting product evaluation, qualification and commercialization across IBT’s global life-science customer network.
●
Proliant Health & Biologicals: Proliant has begun commercialization of Albufree™ DX recombinant human albumin for life science and diagnostic applications and announced plans to expand the Albufree™ portfolio with Albufree™ TX for cell culture and Albufree™ CGT for cell and gene therapy applications, positioning Dyadic for future royalties.
●
Fermbox Bio: Scaled commercialization and initial orders for recombinant DNase I (RNase-free) and recombinant human transferrin.
● Inzymes: Confirmed initial commercial sales of non-animal bovine chymosin, with a second product in development that could trigger milestone payments and royalties.
● Cell Culture & Life-Science Products: Continued advancing animal-free recombinant proteins for cell-culture and related applications. Pilot-scale process improvements increased recombinant human transferrin productivity by approximately 80%, further supporting the potential for competitive manufacturing economics as Dyadic advances transferrin, albumin, growth factors and other recombinant animal-free proteins toward broader commercial use.
●
Food & Nutrition Pipeline Expansion: Initiated scale-up activities with BRIG BIO for recombinant bovine alpha-lactalbumin under a funded development agreement. Subsequent to quarter-end, Dyadic expanded its precision-fermented dairy protein portfolio through an additional development and commercialization agreement, broadening potential opportunities to generate future product, licensing and royalty revenues.
● Global Health Programs: Advanced Gates Foundation-funded RSV and malaria monoclonal antibody (“mAb”) programs, with C1-produced antibodies demonstrating high productivity and functional characteristics comparable to established mammalian-cell reference materials. Funding is in place to advance these programs, and Dyadic is working toward delivery of C1-produced material to support initiation of preclinical studies with one or both mAbs, providing an additional opportunity to support potential future clinical and commercial adoption.
Continued C1 development with CEPI/Fondazione Biotecnopolo di Siena (“FBS”) to accelerate protein-vaccine antigen development and advancing NIAID-supported preclinical evaluation of C1-produced malaria antigens.
●
Rapid Pandemic Response Capabilities: Demonstrated C1’s platform agility by producing, purifying and delivering two Scripps-designed Bundibugyo ebolavirus (“BDBV”) antigens to Scripps Research and FBS in approximately 15 days from plasmid to purified protein. The antigens are undergoing further characterization and may support future preclinical evaluation, subject to program priorities, additional evaluation and available funding.
● Government, Academic & Industry Adoption: Continued monoclonal anti
May 13, 2026 · 100% conf.
1D
+2.17%
$0.73
Act: -2.89%
5D
+6.27%
$0.76
Act: +3.81%
20D
+9.47%
$0.78
Act: -3.97%
2 ex99-1.htm
Exhibit 99.1
● Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry
● Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales
● Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership, while advancing scale-up and commercialization activities for additional recombinant products, including transferrin
● Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant products, with initial product quantities completed for shipment to support commercialization through IBT’s global distribution channels
● Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin for global nutrition markets, which includes funded development, milestones, and potential revenue participation
● Continued advancement of Gates Foundation-supported RSV and malaria antibody programs and the CEPI/FBS H5 avian influenza program, leveraging AI-enabled target development and generating additional validation of Dyadic’s C1 platform
● Cash, cash equivalents, restricted cash and investment grade securities of approximately $6.6 million as of March 31, 2026
● Dyadic to host an earnings call today at 5:00 pm ET
Fla., May 13, 2026 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for Q1 2026 along with significant corporate achievements.
“Throughout 2025 and into early 2026, we remained focused on transforming Dyadic into a commercially driven organization by leveraging our proprietary microbial production platforms to bring animal-free recombinant proteins and enzymes to market, both independently and through strategic partnerships,” said Joe Hazelton, President and Chief Operating Officer of Dyadic. “We are encouraged that these products are now moving through commercial sales channels and reaching customers, demonstrating the scalability of our technology platforms and the increasing market demand for our products. As our distribution partners broaden their reach and customer adoption continues to expand across cell culture media and biomanufacturing applications supporting key growth markets such as cell and gene therapy, biologics manufacturing, and emerging markets such as cultivated meat, we believe Dyadic is well positioned to drive increasing product revenues. At the same time, we are expanding our business development initiatives across Europe to build on the momentum we are achieving in Japan through our collaboration with Intralink.”
Recent Company Developments and Updates
Life Sciences
● Recombinant Serum Albumin (AlbuFree™ DX): In February 2026, Proliant Health and Biologicals announced the commercial launch of AlbuFree™ DX recombinant human albumin, produced using Dyadic’s production platform. Dyadic is entitled to a share of profits from commercial sales.
● OEM Distribution Agreement with IBT Bioservices: In March 2026, Dyadic entered into an OEM distribution agreement with IBT Bioservices to support commercialization of multiple recombinant proteins and enzymes through IBT’s global distribution channels. Initial product quantities, including DNase I and transferrin, have been completed and shipped to support channel commercialization activities.
● DNase-1 (RNase-free): Dyadic completed production validation of recombinant DNase I and, together with Fermbox Bio, commercially launched DNase I (RNase-free) as the first product under their expanded collaboration.
● Recombinant Transferrin and Growth Factors: Dyadic continues advancing its animal-free transferrin and fibroblast growth factor (FGF) products for use in cell culture media, diagnostics, and research, with expanded customer interest and sampling activity for recombinant bovine transferrin within the cultivated meat industry.
● Reagent Proteins and Nucleic Acid Enzymes: Dyadic continues advancing a portfolio of enzymes for DNA and RNA manipulation, including RNase inhibitors and T7 RNA polymerase.
Food and Nutrition
● Alpha-Lactalbumin: In December 2025, Dyadic signed a development and commercialization agreement with BRIG Bio to create recombinant bovine alpha-lactalbumin for global nutrition markets. Product development activities have been initiated, including initial product quality and application testing, with customer sampling activities expected
This page provides Dyadic International Inc. (DYAI) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DYAI's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.